Octa Phillip Bioscience Managers provision of management services and support to Union MedTech Plc, the UK listed medical technology investment vehicle, today received a boost with Union Medtech’s announcement of the appointment of Dr William (Bill) Hunter to its board.
William Hunter co-founded Angiotech Pharmaceuticals in 1992 while still being a medical student at university. Angiotech became a profitable diversified healthcare company quoted on NASDAQ, which at its peak was worth $1.9 billion.
Mr Hunter’s addition to the Board further strengthens the Company’s global network in the medical technology sector which is focusing on a range of opportunities. His expertise and knowledge base has been particularly focused on the North American and European markets.
Octa Phillip Bioscience Managers are currently reviewing a number of opportunities across New Zealand and Australia on behalf of Union Medtech. “Bill’s experience in the global biomedical space is a huge asset to Union Medtech and the international expert advisory network of Octa Phillip Bioscience Managers, “said Bioscience Managers Managing Director and Director of Union Medtech, Jeremy Curnock Cook.
“Being able to bring Bill’s knowledge, expertise and networks into both UMT and our activities within the Asia Pacific, offers the companies we work with access to a true global leader.”
Union Medtech plc Chairman, Christopher Stainforth commented. “We are delighted to have Bill on board – he has a wealth of experience, contacts and know-how, which will prove invaluable as we develop our acquisition strategy. We continue to evaluate a number of prospects and look forward to updating the market further in due course.”